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SUMMARY 
The suppression of plasma corticosterone (B), measured by radioimmunoassay (R1A), was 
compared to simultaneous suppression of plasma cortisol (F), measured as total corticoids by a 
competitive protein binding (CPB) assay, in the overnight dexamethasone suppression test (DST). 
Baseline plasma B concentrations in I0 control subjects were 4.04 ± 1.07 ng/ml (X ± S.D.) at 0800 
hr and 1.51 ± 0.68 ng/ml at 1600 hr. Post-dexamethasone 1600 hr B levels in the controls were 
0.46 ± 0.29 ng/ml. An early escape of plasma B (> 1.2 ng/ml), like that of F (> 5 l~g/dl), during 
the overnight 24 hr 1.0 mg dose DST was noted in patients with melancholia (endogenous 
depression). 
Half-hourly catheter samples in a normal subject stimulated to escape from dexamethasone 
suppression showed that in general, plasma B concentrations parallel plasma F concentrations 
over a 12 hr period. Repeated weekly DSTs on two patients with different psychiatric diagnoses 
resulted in B : F correlations of 0.74 and 0.60. Overall agreement between B- and F-DST 
outcomes in all categories tested at 1600 and 2300 hr was 93°/0; the agreement in the melancholic 
and non-endogenous depressed groups was 100e/o. 
Post-dexamethasone, both B and F were suppressed 55-60e/o below the criterion level in 
controls. In those patients who escaped from dexamethasone suppression, the percentage increase 
in plasma B above the criterion level was significantly greater (+ 550/o) than the corresponding 
percentage change in plasma F. Most patients with borderline abnormal F-DSTs (3.5 -4 .9  gg/dl) 
exhibited clearly abnormal B-DSTs (> 1.2 ng/ml). We conclude that the use of dexamethasone 
suppression of plasma B (using 1.2 ng/ml as the abnormal criterion value) is an additional 
indicator of an abnormal DST in depressed patients. 
Keywords--Cortisol; corticosterone; dexamethasone suppression test; hypothalamic - pituitary - 
adrenocortieal system; melancholia; depression. 
INTRODUCTION 
PATIENTS with endogenous depression (melancholia) frequently have disinhibited activity 
of the hypothalamic - pituitary- adrenocortical (HPA) system. This disinhibition is seen 
most specifically in the dexamethasone suppression test (DST) of HPA function. 
Abnormal DST results may be useful in the diagnosis of melancholia (Carroll et al., 
1976a; 1976b; 1981; Brown et al., 1979; Schlesser et al., 1980; Carroll, 1982). When oral 
dexamethasone is given at 2300-2400 hr, normal subjects maintain plasma cortisol (F) 
suppression below 5 ttg/dl for at least the next 24 hr. Patients with melancholia may 
suppress their plasma F concentrations temporarily, but they often fail to maintain 
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plasma F suppression below 5 I~g/dl for 24 hr. The a b n o r m a l  escape of  p lasma F 
concen t ra t ion  usual ly occurs by 1600 hr and may be observed as early as 0800 hr (Carroll  
e t a l . ,  1976a; 1976b; 1981; Carrol l ,  1982). 
In melanchol ia  the secret ion rate of the ' m i n o r '  h u m a n  glucocort icoid,  cort icosterone 
(B), is increased to a similar extent as that of  cortisol (F) (Gibbons ,  1966). Both F and  B 
are produced in similar regions of the adrenal  cortex, and  both  are modula ted  by the H P A  
system, i.e. regulated by A C T H  (Krieger, 1979; Hard ing ,  1979). Studies in humans  (Oddie 
et  al.,  1972; Nabors  et  al. ,  1974; Ma t sumura ,  1980) reported 70-900/0  suppression of 
bo th  B and  F 4 - 8  hr pos t -dexamethasone  (Table  I). More  impor tan t ly ,  both these 
studies, and  in v i tro  studies as well (Kahri et  al. ,  1979), revealed that the rate of B 
secretion or percentage increase in B levels is 2 - 3 t imes greater than that of  F in response 
to adrenal  s t imula t ion  by endogenous  or exogenous A C T H .  
We have investigated plasma B and  F concent ra t ions  dur ing  the DST to determine 
whether  p lasma B concent ra t ions  give the same diagnost ic  i n f o r ma t i on  for melanchol ia  as 
p lasma F. Knowing  the different ial  responses of p lasma B and  F to A C T H ,  we checked 
par t icular ly  to see if p lasma B more  accurately assessed those pat ients  with border l ine  
a b n o r m a l  F-DST values ( 3 . 5 -  4.9 I~g/dl) (Carroll  e t a / . ,  1981). 
METHODS 
Patients were studied at the Clinical Studies Unit, Department of Psychiatry, University of Michigan, where 
they received diagnostic evaluations as described previously (Carroll et al., 1976a; 1976b; 1980;. 1981). For the 
diagnosis of melancholia, we required agreement between the clinical assessment and the Research Diagnostic 
Criteria (RDC) (Spitzer & Endicott, 1975). All other diagnoses were made according to the RDC; The reliability 
of these diagnoses was high (kappa 0.80). Severity of depression was recorded by the Hamilton Rating 
Scale (HRS) (Hamilton, 1960), with a coefficient of variation among raters of 6%. The DST was performed as 
described by Carroll et al. (1981). An oral dose of dexamethasone (1.0 rag) was given at 2300 hr; blood samples 
obtained the following day at 1600 hr in l l2 tests and at 2300 hr in 26 tests were selected for the simultaneous 
assay of B and F concentrations. 
Ten normal, drug-free subjects with no current psychiatric disorder were tested with blood samples obtained 
at 0800 and 1600 hr pre-dexamethasone and 1600 hr post,dexamethasone. We studied a total of 25 patients from 
several diagnostic groups, as listed in Table II. We used repeated DSTs obtained over time from many individual 
patients. Thus, the focus of this study was the comparative suppression of F and B rather than the diagnostic 
sensitivity and specificity of the two steroids in a large group of patients. 
For the study of borderline abnormal F-DST results, we searched our stored plasma samples for 8 cases in 
which the F concentration post-dexamethasone was between 3.5 and 5.0 I~g/dl. Plasma samples had been kept at 
0°C for six months to one year, with no detectable changes in either B or F concentrations over this time. For 
this study we used samples obtained in any previous DSTs, regardless of whether the time of collection was 0800, 
1600, or 2300 hr (Table III). The following additional studies were performed: (1) a venous catheter study was 
carried out by measuring plasma concentrations of F and B at 30 rain intervals for 12 hr in one normal subject. 
To elicit an escape of plasma F post-dexamethasone, L-DOPA (100 rag) was administered intravenously (Haskett 
et al., unpublished results). (2) Longitudinal studies of serial DSTs at weekly intervals over four to seven months 
were run on two outpatients (J.L.B. and L.S.T.), and the corresponding 1600 hr plasma F and B concentrations 
were compared. 
Determination of  plasma F and B 
Plasma F was measured as total corticoids by a modified competitive protein binding (CPB) method of 
Murphy (1967), with inter- and intraassay coefficients of variation of 11 and 4t/0, res~tively. An ultra-micro 
scale Murphy CPB assay system was used, with 2.0% human serum as the source of cortieosteroid b ~ n g  
globulin (CBG). The standard curve was run in triplicate at con~ntrations of 0, 0.5, 1.0, 2.0, 5,0, 10.0, t5.0 and 
20.0 ng cortisol per 0.2 ml of ethanol. All solvents were redistilled in our laboratory, and the water was of HPLC 
quality, sH-Corticosterone was used as the radioactive ligand in the binding solution. The binding soluiion 
3 consisted of 5 ml of normal human serum, 1.0 ml of 1,2- H~corticosterone (i0 I~Ci/ml and 50-60 ~/mmol), 1.5 
ml ethanol, and water to make a volume of 250 ml. Thus the working concentration of the tracer was 
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0.04 )tCi/ml. Care was taken in preparing the binding solution so as not to precipitate the serum proteins when 
adding the ethanol and the tracer. The binding solution was incubated at 4°C for at least 24 hr prior to use and 
was stable for 10 days. Duplicate aliquots of a 1 : 2 ethanolic extract of patient's heparinized plasma were used 
for the first assay of every sample. The sample extracts and standards were taken to dryness under an air stream 
in a 45°C water bath. Quality control (QC) samples (treated as patient plasmas) were always included at low, 
intermediate and high concentrations (2.9, 5.1 and 10.2 ttg/dl). In each assay no more than 141 tubes (stds, QC 
or patient samples) were included. One millilitre of binding solution was added to each assay tube. The tubes 
were mixed and incubated at 45°C for 10 min, then transferred to an ice-bath (4°C) for 20 min. Approximately 
40 mg of predried florisil (magnesium silicate) then was added to each tube. The tubes were shaken for 2 rain and 
then placed back into the ice bath for 10 min. The florisil absorbed all unbound cortisol, leaving the bound 
ligands in solution. The tubes next were centrifuged (2000 g, 2°C, 6 min) and 0.5 ml of clear supernatant was 
transferred to a scintillation vial. Extreme care was taken during this step, so as not to pipette any florisil from 
the bottom of the tube. Four millilitres PPO/POPOP scintillation cocktail was added to each vial. The vials 
were shaken and counted to 20,000 cpm or 7 rain, whichever came first. Under these conditions, as stated by 
Murphy (1967), time to count is linear with respect to concentration. Quench correction was not necessary, due 
to the ethanol extraction and the extraction of the tracer into the scintillation cocktail. 
When the first determined patient value was > 3 and < 7 ttg/dl, the sample was re-assayed with three varying 
sized aliquots of the ethanolic extraction to provide at least two separate and duplicate estimates on the steep 
portion of the binding curve. The mean of these four is reported. While this double-checking often is redundant, 
it improves the precision of the assay in this critical range. 
The assay for plasma B was based on the most recent procedure and antiserum (B3-163) obtained from 
Endocrine Sciences (Tarzana, CA). The antiserum was used at a dilution of 1/64,500, and the standard curves 
ranged from 0 to 750 pg/tube. Interfering steroids (e.g. F and progesterone) were removed by extraction of the 
plasma (300 ttl) into hexane : benzene (80 : 20, v/v) and then hexane : benzene (20 : 80, v/v). Triplicate tubes 
with either standards or plasma extracts were incubated at room temperature for 2.5 hr in a mixture containing 
0.05 M borate buffer (pH 8.0), 1,2-()H)corticosterone, 60 Ci/mmol (New England Nuclear, No. NET-182), 10070 
bovine serum albumin (Schwarz/Mann, No. 751), 0.5070 bovine gamma globulin (Schwarz/Mann, No. 3004), 
and antiserum. To determine non-specific binding to the assay tubes, triplicate tubes likewise were incubated in a 
similar buffer solution without antiserum. The two-step organic extraction procedure minimized nonspecific 
protein binding from the plasma samples. Saturated ammonium sulfate was added to separate the bound from 
the free B, and the free fraction then was extracted and counted. Final values were calculated with correction for 
the recovery of labelled B, which averaged 60.35070 (S.E. 1.93%) through the entire method. The cross-reactivity 
of the antiserum to cortisol, progesterone and dexamethasone was 0.4, 0.6 and 0.0507o, respectively. The 
extraction procedure removed 92.107e of the cortisol, 85070 of the progesterone and 68% of the dexamethasone. 
Thus, in the assay system an original plasma F concentration of 100 ng/ml (10 I~g/dl) would cause negligible 
displacement of tritiated corticosterone, equivalent to 0.03 ng/ml. The interfering effects of other steroids 
similarly were negligible. The inter- and intra-assay coefficients of variation were 19 and 8070, respectively, as 
determined by analysis of pooled human sera at concentrations above and below the 50070 binding of the 
standard curve. The lower limit of sensitivity of the assay was 0.2 ng/ml. Due to the high interassay variation, 
patient samples were randomized into 10 different assays. All longitudinal and catheter studies were analyzed in 
single assays. 
The half-lives of B and F in plasma during the 12 hr venous catheter study were determined as described by 
Carroll (1972). 
Statistical analysis 
Statistical comparisons between experimental groups were evaluated by Students t-test (two-tailed). Sensitivity 
and specificity results were calculated according to standard conditional probability principles (Vecchio, 1966; 
Galen & Gambino, 1975). 
RESULTS 
Normal  subjects 
T h e  0800  h r  b a s e l i n e  p l a s m a  B v a l u e s  in  t h e  n o r m a l  s u b j e c t s  ( T a b l e  I) a g r e e d  we l l  w i t h  
p r e v i o u s  s t u d i e s  in  w h i c h  m o r n i n g  B p l a s m a  c o n c e n t r a t i o n s  r a n g e d  f r o m  2 .4  n g / m l  
( K o b a y a s h i  et al., 1979) t o  6.1 n g / m l  ( M a t s u m u r a ,  1980) .  N o  sex d i f f e r e n c e  in  t h e  p l a s m a  
B o r  F c o n c e n t r a t i o n s  w a s  n o t e d  w i t h i n  c o n t r o l s  o r  a m o n g  t h e  v a r i o u s  e x p e r i m e n t a l  
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groups (data not shown). The marked difference between the 0800 and 1600 hr baseline 
plasma B values agrees with the report of  Nabors et  al. (1974). 
After dexamethasone there was a clear suppression of plasma B concentrations (Table 
I). Though measured at 1600 instead of  0800 hr, the post-dexamethasone plasma B values 
and the percentage suppression (70°7o) agree closely with other studies (Meikle et  al., 1974; 
Nabors  et  al., 1974). 
TABLE I. PLASMA CORTICOSTERONE CONCENTRATIONS lN NORMAL SUBJECTS PRE- AND POST-DEXAMETHASONE 
Basel ine Post -dexamethasone:~ 
Reference  X _+ S.D. (n)* T i m e s  X ± S.D. (n)* T i m e r  
Current 4.04 _+. 1.07 (6) 0800 Not determined 
Study 1.51 ± 0.68 (10) 1600 0.46 ± 0.29 (10) 1600 
Oddie et aL (1972) 4.20 ± 0.90 (17) 0900 Not determined 
Kobayashi et al. (1979) 2.40 ± 4.02 (20) 0930 Not determined 
Meikle et al. (1974) 4.76 ± 3.00 (1 I) 0800 0.47 _+ 0.15 (11) 0800 
Nabors et al. (1974) 5.25 ± 2.50 (30) 0800 0.46 ± 0.16 (11) 0800 
Matsumura (1980) 6.10 ± 2.70 (9) 0900 1.80 ± 0.50 (9) 0400 
*Values are expressed in ng/ml _+ S.D. 
tlndicates time of blood sampling. 
~Dexamethasone (1.0 rag) was given orally to subjects in all studies at 2300 hr of the preceding night. 
12 -Hour  ca the ter  s t u d y  
Plasma concentrations of  F and B post-dexamethasone were measured at 30 min 
intervals for 12 hr in a normal subject who had received dexamethasone (1 mg) the 
previous day at 2300 hr (Fig. 1). L-DOPA (100 mg) was administered intravenously over 
15 mins to elicit an escape of  plasma F (Haskett ,  et  al., unpublished results). There was a 
marked similarity in the concurrent secretion of  B and F after L-DOPA. Between 1415 
and 1615 hr, the percentage escapes of  F and B compared to their suppressed baselines 
(1000 to 1400 hr) were 380 and 500o70, respectively. In addition to this differential escape, 
the plasma half-lives of  clearance following the secretory episodes differed, as determined 
on the five points between 1515 and 1630 hr, being 50.2 and 33.5 min for F and B, 
respectively. 
P a t i e n t  g r o u p s  
We compared the p lasma B and F results in a total of  112 DSTs. In all tests the 1600 hr 
post-dexamethasone blood sample was obtained. In 26 tests we also obtained the 2300 hr 
post-dexamethasone sample. Thus, we compared the B and F suppression response in a 
total of  138 post-dexamethasone blood samples (Table II). Using the plasma F result, the 
criterion value of an abnormal  DST result was > 5 Ixg/dl. For the plasma B result we set a 
criterion value > 1.2 ng/ml ,  as suggested by Meikle et  al. (1974). 
Overall, the DST results by the two criteria agreed in 128 of  138 comparisons (93q0). 
Eight of  the 10 disagreements occurred in patients with rapidly cycling bipolar affective 
disorder. In the two other disagreements (one schizo-affective and one non-endogenous 
depression), the F-DST result was borderline abnormal  (see below). At the 1600 hr 
sampling time there was 100°70 agreement for normal  subjects, melancholic patients, non- 
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FIG. 1. Plasma F ( - - )  and B ( O - - O )  levels from 30 min catheter samples in a normal subject. 
Dexamethasone (1.0 mg) was given orally at 2330 hr the preceding night, and L-DOPA (100 mg i.v.) was given at 
1425 - 1440 hr. The B - F correlation coefficient was 0.90. 
TABLE 1I. A G R E E M E N T  OF C O R T I C O S T E R O N E  A N D  C O R T I S O L  DST R E S U L T S *  
1600 hr 2300 hr 
Group(n)  Agreements/tests (070 Agreement) Agreements/tests (070 Agreement) 
Normal subjects (10) 10/10 (100%) - -  - -  
Melancholia (5) 32/32 (100%) 8/8 (100070) 
Rapid cycling bipolar patients (4) 40/48J (83070) I/1 (10007o) 
Mixed manic-depressive (4) 8/8 (100070) 4/4 (100070) 
Non-endogenous depression (4) 5/5 (100070) 4/5:[: (80070) 
Schizoaffective (4) 4/5:~ (80%) 4/4 (10007o) 
Borderline personality disorder (4) 4/4 (100070) 4/4 (100070) 
Overall (25) 103/1 12 (92070) 25/26 (96070) 
Total 128/138 (93070) 
*DST plasma B results (abnormal B-DST > 1.2 ng/ml) were compared to corresponding plasma F results 
(abnormal > 5 I.tg/dl). 
tThe disagreements were six, normal B-DST, abnormal F-DST; two, normal F-DST, abnormal B-DST. 
~tThe disagreement was normal F-DST, abnormal B-DST. 
endogenous depressives, mixed manic-depressives, and patients with borderline 
personality disorder. 
Borderline abnormal F-DSTs 
From previously reported studies of  the F-DST (Carroll et al., 1981; Fig. 3) the plasma 
F range of  3 . 5 - 4 . 9  txg/dl can be considered as borderline or transitional between 
definitely normal and definitely abnormal results. Table III lists the results of all post- 
dexamethasone samples (n = 8) in which the F values were borderline abnormal. In seven 
of these eight cases, the B concentrations clearly were elevated. Additionally, in the cases 
where the 0800 hr B value indicated an abnormal DST and F was borderline abnormal 
(Patients Nos. 1, 2, 6 and 7), the subsequent 1600 hr F values also indicated an abnormal 
DST (> 5 p.g/dl) (data not shown). 
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TABLE I11. PLASMA CORTISOL AND CORTICOSTERONE CONCENTRATIONS IN SIX PATIENTS WITH BORDERLINE ABNORMAl 
DSTs* 
Plasma Plasma 
Patient cortisol cort icosteronet 
No. Sex Time (lig/dl)  (ng/ml)  
1 F 0800 3.65 1.95 
2 M 0800 3.71 1.55 
3 F 1600 4.50 2.92 
4 M 2300 3.88 1.94 
5 F 1600 4.78 1.51 
6 F 0800 4.51 1.92 
7 M 0800 4.50 1.46 
8 F 1600 4.80 1.14 
*Post-dexamethasone (1 mg at 2300 the preceding night) plasma F concentrations of 3.5 - 4.9 t ig/dl  constitute 
a borderline abnormal DST. 
i 'Normal post-dexamethasone plasma B is less than 1.2 ng /ml  (Meikle et aL, 1974). 
Longitudinal outpatient studies 
Two patients were studied with repeated DSTs over four and seven months, respectively 
(Figs. 2 and 3). The Pearson: product-moment correlation between the 1600 hr post- 
dexamethasone plasma B and F concentrations for the 18 tests in JLB (Fig. 2) was 0.74 
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FIG. 2. Plasma F( - - ) and B(O - - O) I600 hr levels from repeated weekly outpatient DSTs on a melancholic 
outpatient. The overall B -  F correlation was 0.74, and the agreement of the B : F DST outcome was 100% 
(18/18). 
Patient JLB was a woman with bipolar H affective disorder who developed a severe 
depression each year in the spring and in the autumn. During the study shown in Fig. 2 
and for four weeks before the study began she was taking lithium carbonate (1200 
mg/day) and tranylcypromine (90 mg/day) continuously. A direct drug effect on the 
hormone concentrations therefore was considered unlikely, since both F and B changed in 
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parallel and lithium causes only a brief (< seven days) alteration in mineralocorticoid 
secretion. The study began in July 1981, as she was recovering from her spring depression. 
Eighteen consecutive DSTs with 1600 hr blood sampling were performed. A single 
abnormal result (by both B and F criteria) was observed in the first 11 tests. The next three 
consecutive abnormal tests that occurred just before and then after day 90 actually 
preceded the sudden onset of her next depression in mid-October, 1981. In these tests, as 
in the final four of the study when she was severely depressed, the plasma B elevation was 
proportionately much greater than the rise in plasma F values. Nevertheless, the 1600 hr 
DST results by both B and F criteria were in agreement for all 18 tests. 
Patient LST was a woman with rapidly cycling bipolar affective disorder. The HRS 
scores in Fig. 3 illustrate seven brief episodes of depression during the seven months she 
was studied. When the HRS scores were low this patient was usually hypomanic, 
sometimes mildly manic. She was treated with lithium carbonate (2100 mg/day) from day 
15 until the end of the study. The four normal F-DST results we observed occurred at 
times of low HRS depression ratings. Abnormal F-DST results during the first 120 days of 
the study occurred either with or just before a switch to high depression ratings (see 
Greden et al., 1982). During the second half of the study, her recurrent depressive 
episodes were attenuated, but abnormal F-DST results continued. 
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FKI. 3. P l a s m a  F ( - - ) and  B ( O -  - O) 1600 hr levels f rom repeated  ou tpa t i en t  DSTs and  the co r r e spond ing  
cl inical  phase  d a t a  by H a m i l t o n  Ra t ing  Scale (HRS)  on  a rapid  cycl ing pat ient .  A r r o w s  indica te  d i sag reemen t s  of  
B- and  F-DST results .  The  overa l l  B - F cor re la t ion  was 0.60, and  the ag reemen t  of  the B : F DST o u t c o m e  was 
77°7o 0 3 / 1 7 ) .  
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In this patient, four of the 17 tests (indicated by arrows in Fig. 3) gave discordant 
results. In two instances, B was elevated but F was not, while the reverse pattern was seen 
in the other two tests. These discrepancies are included with the others in Table II (rapid 
cycling bipolar patients). 
Comparison of  B and F deviations f rom criterion values 
The mean plasma B and F values found in normal and abnormal DSTs are shown in 
Fig. 4 in relation to the corresponding criterion values (B = 1.2 ng/ml; F = 5 ~tg/dl; 
n = 174). No significant differences were noted between B and F in normal DSTs, in 
which mean B and F levels were suppressed below the criterion values by 55 and 60°70, 
respectively. In the abnormal tests, the magnitude of B increase (+210°70) was 
significantly greater than the corresponding increase in F levels (+  13507o) (p < 0.005). 
This finding agrees with all other studies that report the differential relative responses of B 
and F to adrenal stimulation (Oddie et al., 1972; Nabors et al., 1974; Kahri et al., 1979; 
Matsumura, 1980), and is in agreement with the results in Fig. 1. 
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FIG. 4. These results are the cumulation of all normal (n = 76) and abnormal (n = 68) 0800, 1600 and 2300 hr 
samples (from 23 patients). Percent deviation from abnormal DST criterion value was determined by comparing 
individual samples with the corresponding F and B criteria values of 5 ttg/dl and 1.2 ng/ml, respectively. DST 
percent deviation values were significantly different between B and F using a Student's t-test (two-tailed, 
d f  = 140, P < 0.05). There was no significant difference between the percent deviation in B and F in a normal 
DST. 
DISCUSSION 
There is a variety of techniques presently used to measure plasma concentrations of B. 
Reported values of 0800 hr plasma B in humans range from as low as 2.4 ng/ml (enzyme 
immunoassay, Kobayashi et al., 1979) to as high as 6.1 ng/ml (radioimmunoassay, 
Matsumura, 1980). Plasma B levels reported here were determined using a single antibody 
radioimrnunoassay with a two-step pre-extraction into benzene, sensitive down to 0.2 
ng/ml, and lacking major interfering cross-reactions. Our data confirm other reports 
showing that (I) there was no sex difference in plasma B concentrations at any time; (2) 
dexamcthasone suppressed plasma B concentrations by 70-90o/0 (Meikle et at., 1974; 
PLASMA F and BtN THE DST 53 
Nabors et  al., 1974; Matsumura, 1980); (3) B was secreted in an episodic manner along 
with F (Nabors et  ai., 1974); (4) the proportionate increase of plasma B was greater than 
that of plasma F over suppressed values in response to adrenal stimulation (Fig. l) (Oddie 
et  al., 1972; Nabors et  al.,  1974; Kahri et  al., 1979; Matsumura, 1980); and (5) the half-life 
of clearance of B from plasma is more rapid than that of F following a secretory episode 
(Fig. 1) (Brooks et  al., 1972; Nabors et  al., 1974). In addition, we have shown that 
baseline afternoon plasma B concentrations in normal subjects are lower than morning 
values (Table I). 
The parallel secretion of B and F is shown in Fig. 1, where L-DOPA was administered to 
stimulate the HPA axis pharmacologically (Haskett et  ai., unpublished results). Though 
the significance of this effect of L-DOPA is not to be addressed in this paper, this catheter 
study illustrates the parallel secretion and control of B and F secretion by ACTH. It also 
demonstrates the greater response of B to ACTH and the more rapid clearance of B after 
the secretory episode. 
Meikle and associates (1974) reported that in patients with Cushing's Syndrome either a 
50°70 decrease of the baseline B value or a criterion plasma B concentration of 1.2 ng/ml 
post-dexamethasone indicated non-suppression. The results in Table II show that by using 
the criterion value of 1.2 ng/ml, plasma B can be used to accurately identify depressed 
patients with abnormal DSTs. The DST results given by the plasma F and B criteria 
agreed in 93070 of 138 comparisons (Table II). The apparent specificity of the B-DST in 
this small number of patients was 95070. This figure is based on the results in normal 
subjects and nonendogenous depressives, where 19 of 20 results were normal (Table II). 
The reported specificity of the F-DST in a much larger population is 96°70 (Carroll et  al., 
1981). At the same time, the sensitivity of the B-DST may prove to be somewhat higher 
than that of the F-DST, since in seven of eight cases where the F result was borderline 
abnormal (3.5- 5.0 pg/dl), the B result was definitely elevated. 
Similarly, in the longitudinal studies of individual patients (Figs. 2 and 3), there was 
generally good agreement between the DST results by both the plasma F and the plasma B 
criteria. In subject JLB (Fig. 2) the results agreed in all 18 tests. In the rapidly cycling 
bipolar patient (Fig. 3) the DST results disagreed in four of 17 tests. This group of patients 
contributed almost all the disagreements noted in Table II. In fact, if this group were to be 
excluded, then the B-DST : F-DST agreement in the other groups of patients in Table II 
would be 9807o (87 of 89 tests). We do not know why the rapidly cycling bipolar patients 
should have had such a high frequency of disagreements (eight of 49 comparisons, or 
16%; Table II). 
When the DST is performed in psychiatric patients only two or three post- 
dexamethasone blood samples are drawn in a 24 hr period (Carroll et  al., 1981). Since the 
secretion of corticosteroids is episodic, single blood samples may be taken by chance 
either at the peak or at the trough of a secretory episode. In principle, therefore, the 
differential proportionate secretion and the differential rate of clearance of B and F may 
be used to advantage in this context. Since B is secreted more vigorously than F, a weak 
pulse of ACTH could raise the plasma B concentration above the criterion value, whereas 
the plasma F concentration is raised only to the range of borderline abnormal values, 
especially if the blood sample is drawn early in a secretory episode. In Fig. 1, for example, 
definitely abnormal plasma B concentrations of 3 - 6  ng/ml would have been found 
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before the plasma F concentration reached the criterion value of 5 ixg/dl on the ascending 
portion of the secretory episode. The results in Table III support this possibility. 
Similarly, blood samples drawn at the end of a secretory episode could yield normal B 
concentrations but abnormal F concentrations, especially if the respective rates of 
clearance of the two steroids differed more widely than in the subject shown in Fig. 1. 
Overall, we observed eight examples of the first type of B-F disagreement and six 
examples of the second type (Tables II and III). We suggest that these disagreements are 
due to the physiological mechanisms mentioned above. 
Recently, Holsboer et al. (1982a; 1982b) also reported on plasma B responses in the 
DST with depressed patients. They measured several adrenal steroids (F, B, 
l l-deoxycortisol, ll-deoxycorticosterone and cortisone) and concluded that elevated 
concentrations of several adrenal steroid products occurs in depressed patients during the 
DST, sometimes before elevated F values. In particular, they found that high ratios of 
F :  ll-deoxycortisol or B:  ll-deoxycorticosterone often are present, and interpreted 
these elevated ratios to indicate excessive stimulation of the adrenal cortex by ACTH. 
Thus, measurement of the full spectrum of adrenal corticosteroid secretion in depression 
may improve the sensitivity of the DST even further than by simply measuring F and B 
responses. 
In summary, plasma B concentrations may be used instead of plasma F concentrations 
in the DST for melancholia. The specificity and sensitivity appear to be similar for each 
steroid. The DST results agreed in 93°7o of 138 comparisons involving normal subjects and 
several groups of patients. Since the two measures agreed so well overall, we would not 
propose that plasma B concentrations be measured in all DSTs on psychiatric patients. 
For practical purposes, plasma B could be measured only in cases where the F-DST result 
was borderline abnormal (plasma F concentration 3 .5-5 .0  Ixg/dl). A high plasma B 
concentration in such cases would be of potential diagnostic value for melancholia. If the 
plasma F value itself is high, then no further diagnostic information will be obtained from 
the plasma B value. 
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